Welcome to our dedicated page for Senzime Ab news (Ticker: SNZZF), a resource for investors and traders seeking the latest updates and insights on Senzime Ab stock.
Senzime AB reports recurring developments around its TetraGraph neuromuscular monitoring system, hospital contracting in the United States, and commercialization through integrated delivery networks and group purchasing organizations. Company updates also cover TetraCom connectivity, financial reports, margin and cash-flow commentary, and expansion of U.S. sales, clinical, and medical-affairs functions.
Governance-related announcements include annual general meeting notices and shareholder-program proposals, while operating updates focus on anesthesia data transmission, hospital procurement access, system installations, and recurring revenue tied to the installed base.
Senzime (OTCQX:SNZZF) announced senior U.S. leadership changes to strengthen commercial and clinical operations. Josi Wood joins as Vice President of U.S. Sales on May 11, 2026, and Jen Sanders is promoted to Vice President of Clinical and Medical Affairs effective May 1, 2026. G.W. Hamilton moves from President of Senzime Inc. to General Manager of U.S. operations.
The appointments aim to scale U.S. commercial execution and deepen clinical leadership as Senzime advances its perioperative patient-safety offerings.
Senzime (OTCQX:SNZZF) announced that its TetraGraph System was added to agreements with Vizient, Premier, and HealthTrust Performance Group on April 24, 2026. These three GPOs serve roughly 95% of US hospitals and have combined annual purchasing volumes exceeding USD 200 billion. The company said GPO listings remove procurement barriers, may shorten sales cycles with pre-negotiated pricing, and could help convert pipeline opportunities into orders, supporting broader US commercial expansion over time.
Senzime (OTCQX:SNZZF / STO:SEZI) published its 2025 annual and sustainability report on April 24, 2026, available on the company website.
The company reports it exceeded SEK 100 million in sales, increased growth rate, met its sales growth targets in constant currencies, kept costs according to plan, secured several strategic wins, and says it laid the foundation for profitability in 2026.
Senzime (OTCQX:SNZZF) reported Q1 2026 results: net sales SEK 23,233k (‑1%; currency‑adjusted +11%), gross margin 63.1%, operating expenses SEK 35,562k and operating loss before depreciation SEK -20,202k. Profit after financial items was SEK -23,242k and EPS -0.14 SEK.
Cash and cash equivalents were SEK 55,353k with an unused credit facility of SEK 42,500k. Cash flow improved by 33% (SEK 12.7m). Management says US timing shifts temporarily slowed growth but full‑year 2026 targets and profitability guidance remain on track.
Senzime (OTCQX:SNZZF) announced on April 20, 2026 an expanded contract with a leading southeastern US hospital system for an additional 65 TetraGraph systems.
The network will now have over 160 TetraGraph installations, generating an estimated annual recurring revenue > SEK 6 million. Senzime has delivered more than 5,000 TetraGraphs and its solutions are used in over 750 hospitals.
Senzime (OTCQX:SNZZF) calls its Annual General Meeting for 19 May 2026 at 16:00 in Uppsala.
Key items include re-election of board members, no dividend for 2025, proposed board remuneration framework (cash up to SEK 2,025,000 plus share rights), introduction of Class C shares with reduced voting rights, a Board Program 2026, proposals for directed issues and repurchase authorizations, and reappointment of Öhrlings PwC as auditor. Total shares outstanding: 157,215,046.
Senzime (OTCQX:SNZZF) invites investors, analysts and media to presentations of its Q1 2026 report on April 22, 2026. The report will be published at 08:00 CEST, followed by a CEO webcast at 09:00 CEST on Senzime's investor site and a live Q&A at 11:00 CEST hosted by Redeye.
Questions for the Q&A must be emailed by April 22, 10:00 CEST to gustaf.meyer@redeye.se. A recording of the Q&A will be posted later the same day on Redeye's website.
Senzime (OTCQX:SNZZF) announced secured contracts to supply TetraGraph systems to hospitals within a major US integrated delivery network, representing a potential scope of more than 150 hospitals. Initial deliveries to a first group of hospitals have begun, positioning this as potentially the company's largest US system-wide agreement to date.
The TetraGraph monitor is presented as supporting compliance with recent ASA and ESAIC guidelines and aims to optimize neuromuscular blockade dosing, reduce complications, and lower anesthesia drug costs.
Senzime (OTCQX:SNZZF) launched TetraCom on February 19, 2026, a hospital connectivity platform that transmits real-time neuromuscular data from the TetraGraph monitor into major EHRs like Epic and Oracle Health (Cerner).
TetraCom combines a compact hardware gateway and cloud software using HL7 messaging to enable wireless, monitor-independent data interoperability and automated, guideline-compliant documentation; initial availability is in the US market.
Senzime (OTCQX:SNZZF) announced on February 18, 2026 a 50 MSEK credit line facility provided by existing shareholders including Crafoord, Segulah and DBT Capital (part of Noba Bank Group).
The facility combines a term loan and a revolving credit portion for working capital peaks, carries market terms, and contains no warrants or dilutive conversion rights. Management says the funding confirms shareholder commitment and supports rapid growth and working capital flexibility.